-aventis signed a binding agreement to acquire BiPar
Sciences in a deal worth up to $500 million. The purchase price will depend on milestones achieved by BiPar's lead candidate, BSI-201, a potential first-in-class PARP inhibitor.
BSI-201 is currently in Phase II trials. It is being investigated in metastatic triple negative breast cancer (TNBC), ovarian cancer, and other malignancies. PARP inhibitors reportedly prevent cancer cells from repairing their own DNA and ultimately cause cancer cell death.
"The acquisition of BiPar, one of the pioneers for novel tumor-selective therapies, is a further step in our company's goal to focus on new approaches to strengthen our oncology R&D portfolio," says Christopher A. Viehbacher, CEO of Sanofi. "This acquisition illustrates our strong commitment to oncology to provide patients, physicians, and public health stakeholders with breakthrough medicines addressing unmet medical needs."
BSI-201 is a targeted cancer therapy based on an emerging technique called PARP inhibition, says BiPar. The drug is reportedly being studied in breast and ovarian cancer as well as other malignancies.
Sanofi-Aventis to Commercialize AEterna Zentaris’ Late-Stage BPH Drug in the U.S. (Mar. 6, 2009)
Sanofi-Aventis Ups Bid for Zentiva to $2.63B (Sept. 22, 2008)
Dyax and Sanofi-Aventis Ink Oncology Antibody Deal Worth $500M (Feb. 12, 2008)
Sanofi-aventis Inks Partnership with Regeneron Valued at $560M (Nov. 29, 2007)
BiPar Finds Overexpressed Protein in Specific Cancers (Oct. 26, 2007)